These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16863500)

  • 1. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical aspects of continuous intravenous treprostinil therapy.
    Widlitz AC; McDevitt S; Ward GR; Krichman A
    Crit Care Nurse; 2007 Apr; 27(2):41-2, 44-5, 47-50; quiz 51. PubMed ID: 17389412
    [No Abstract]   [Full Text] [Related]  

  • 5. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
    Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
    Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evaluation of continuous intravenous epoprostenol.
    Chaumais MC; Jobard M; Huertas A; Vignand-Courtin C; Humbert M; Sitbon O; Rieutord A; Montani D
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1587-98. PubMed ID: 21077785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension.
    Hellawell JL; Bhattacharya S; Farber HW
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1445-53. PubMed ID: 25204984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
    Stream AR; Bull TM
    Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
    Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ;
    J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient safety challenges in treprostinil therapy.
    Roncesvalles A; Lee FW; Camamo J; Priestley G
    Medsurg Nurs; 2008 Apr; 17(2):101-6. PubMed ID: 18517170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.